Impact of the conditioning regimen - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 167

References
[1] Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradia-
tion, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory
cytokine release and development of acute and chronic graft-versus-host disease in H-2-
incompatible transplanted SCID mice. Blood 1994;83(8):2360-7.
[2] Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation
is a simple and effective way to reduce acute graft-versus-host disease mortality after
major H2 incompatible transplantation. Transplantation 1997;64(2):297-302.
[3] Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and
acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory
cytokines. Blood 1997;90(8):3204-13.
[4] Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL. Pretransplant chemotherapy
reduces inflammatory cytokine production and acute graft-versus-host disease after
allogeneic bone marrow transplantation. Transplantation 1999;67(11):1478-80.
[5] Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, Thomas ED. Long-term follow-
up of a randomized trial of two irradiation regimens for patients receiving allogeneic mar-
row transplants during first remission of acute myeloid leukemia. Blood 1998;92(4):1455-6.
[6] Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al. Alloge-
neic marrow transplantation in patients with acute myeloid leukemia in first remission:
a randomized trial of two irradiation regimens. Blood 1990;76(9):1867-71.
[7] Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk fac-
tors for acute GVHD and survival after hematopoietic cell transplantation. Blood
2012;119(1):296-307.
[8] Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell
transplantation. Leuk Lymphoma 2005;46(9):1251-60.
[9] Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al.
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic
stem cell transplantation. Blood 2003;102(2):756-62.
[10] van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal
lesions from graft-versus-host reaction. J Natl Cancer Inst 1977;58(3):787-90.
[11] van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary
disease of allogeneic mouse radiation chimeras by modification of the intestinal micro-
flora. J Natl Cancer Inst 1974;52(2):401-4.
[12] Clouthier SG, Cooke KR, Teshima T, Lowler KP, Liu C, Connolly K, et al. Repifermin
(keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while pre-
serving a graft-versus-leukemia effect. Biol Blood Marrow Transplant 2003;9(9):592-603.
[13] Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate
immune response in the pathophysiology of acute graft versus host disease. J Endotoxin
Res 2002;8(6):441-8.
[14] Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, et al. LPS antagonism
reduces graft-versus-host disease and preserves graft-versus-leukemia activity after
experimental bone marrow transplantation. J Clin Invest 2001;107(12):1581-9.
[15] Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al. Hyporesponsive-
ness of donor cells to lipopolysaccharide stimulation reduces the severity of experimen-
tal idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J
Immunol 2000;165(11):6612-9.
[16] Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut
homeostasis. Curr Opin Immunol 2010;22(4):455-60.
[17] Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H, et al. Graft-versus-host
disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-
defensins. Blood 2012 Apr 24. (Epub ahead of print).
[18] Takashima S, Kadowaki M, Aoyama K, Koyama M, Oshima T, Tomizuka K, et al. The Wnt
agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal
stem cells. J Exp Med 2011;208(2):285-94.
[19] Johansson JE, Ekman T. Gut toxicity during hemopoietic stem cell transplantation may
predict acute graft-versus-host disease severity in patients. Dig Dis Sci 2007;52(9):2340-5.
[20] Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, et al. Dose-dependent
effect of etoposide in combination with busulfan plus cyclophosphamide as condition-
ing for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow
Transplant 2000;26(7):711-6.
[21] Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/
II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host dis-
ease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).
Biol Blood Marrow Transplant 2008;14(9):1017-21. PubMed PMID: 18721764; PubMed
Central PMCID: PMC2601713.

169